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BACKGROUND: Hypoxia is as an indicator of poor treatment outcome. Consistently, hypoxic HCT116 colorectal cancer cells are
resistant to oxaliplatin, although the mechanistic basis is unclear. This study sought to investigate the relative contribution of HIF-1
(hypoxia-inducible factor-1)-mediated gene expression and drug penetrance to oxaliplatin resistance using three-dimensional
spheroids.
METHODS: Hypoxia-inducible factor-1a function was suppressed by the stable expression of a dominant-negative form in HCT116
cells (DN). Cells were drug exposed as monolayer or multicellular spheroid cultures. Cells residing at differing oxygenation status
were isolated from Hoechst 33342-treated spheroids using flow cytometry. Sub-populations were subjected to clonogenic survival
assays and to Inductively-Coupled Plasma Mass Spectroscopy to determine oxaliplatin uptake.
RESULTS: In spheroids, a sensitivity gradient (hypoxicoaerobic) was revealed by survival assays and this correlated with levels of
platinum-bound DNA. The resistance of hypoxic sub-populations exceeded relative changes in adduct levels, implicating factors other
than drug penetrance in cell response. Dominant-negative monolayer cells showed no resistance to oxaliplatin in hypoxia and
spheroids; the relative resistance of hypoxic compared with aerobic sub-populations was reduced compared with those from
controls.
CONCLUSION: Overall, data show that drug penetration, DNA damage levels and HIF-1-dependent processes, all contribute to the
resistance of hypoxic cells to oxaliplatin.
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Hypoxia, a common feature of human cancers, is often associated
with poor prognosis (Brown and Wilson, 2004). Impaired drug
penetration into hypoxic regions of tumours was thought to explain
the poor prognosis, but recently an adaptive cellular response to
hypoxia was demonstrated to reduce the cytotoxicity of many drugs.
A central component of hypoxic adaptation is the stabilisation and
activity of hypoxia-inducible factor-1 (HIF-1). Hypoxia-inducible
factor-1 orchestrates the transcriptional regulation of genes involved
in a plethora of cellular processes, including glycolysis, angiogenesis
and metastasis. We previously demonstrated that activation of
HIF-1 provoked changes in apoptosis pathway regulatory protein
levels that affect drug sensitivity (Erler et al, 2004). Furthermore,
inhibition of the HIF-1 function reduces hypoxia-mediated radio-
and chemo-resistance (Moeller et al, 2004; Williams et al, 2005;
Brown et al, 2006; Moeller and Dewhirst, 2006). Consequently, HIF-1
is perceived as a tractable drug target (Stratford et al, 1994; Williams
et al, 2004; Semenza, 2007), and novel anticancer agents targeted to
HIF-1-modulated pathways are being evaluated for clinical use.
Multicellular spheroids that model the hypoxic microenviron-
ment in vivo can be exploited to achieve a more comprehensive
assessment of factors contributing to resistance of hypoxic cells
within tumours (Jones et al, 1982; West et al, 1984; Olive et al,
1996). Moreover, isolation of cell sub-populations from different
spheroid microenvironments allows a detailed mechanistic study
(Olive et al, 1996). Here, monolayer and spheroids of HCT116
colorectal cancer (CRC) cells treated with oxaliplatin were
compared with dissect contributions of drug bioavailability
(reported by DNA adducts), hypoxia and HIF-1 function(s) to
the cellular response to a clinically relevant therapy for CRC.
MATERIALS AND METHODS
All materials were from Sigma-Aldrich (Gillingham, UK) unless
otherwise stated.
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HCT116 human CRC cells were cultured under standard conditions
and were exposed to hypoxia for a minimum of 8h before drug
treatments (details in supplementary methods). Spheroids were formed
as detailed in supplementary methods. Spheroids (B50) were placed
into 3.6ml cryotubes (Nunc, Fisher Scientific, Loughborough, UK) with
1ml media containing drug or vehicle. The tubes were gassed with 5%
CO2/air, sealed and incubated at 371C on a Stuart roller mixer device
(VWR International, Lutterworth, UK). Oxaliplatin (Alexis Biochem-
icals via Axxora (UK) Ltd, Birmingham, UK) was prepared as a 10mM
stock solution in PBS, stored as aliquots at  801C, and was only
subjected to a single freeze-thaw cycle. To treat cells or spheroids, the
stock solution was diluted in media to the appropriate concentration.
Generation and validation of cell lines to investigate HIF-1
The coding sequence of a dominant-negative (DN) HIF-1a
construct (Brown et al, 2006) was cloned into pEFIRESp (Hobbs
et al, 1998). Growing phase HCT116 or HT1080 cells were
transfected with DN or empty vector (EV) using lipofectamine
according to the manufacturer’s instructions (Invitrogen, Paisley,
UK), with puromycin added 48h later. Resistant colonies were
expanded and HIF function was assessed by HRE reporter assay
(Brown et al, 2006). Further validation was carried out by
immunoblotting cell extracts obtained after aerobic or hypoxic
conditions for HIF-1a and the HIF-1 downstream target glucose
transporter-1 (GLUT-1) using the following primary antibodies:
HIF-1a (1:500; BD Transduction Laboratories, Oxford, UK),
GLUT-1 (1:6000, AB1340, Chemicon, Watford, UK) and b-actin
(1:80000; Sigma—Aldrich), followed by horseradish peroxidase-
coupled secondary IgG with resolution by enhanced chemilumi-
nescence.
Cells reporting HIF function were generated by transfecting
HCT116 cells with an LDH-HRE-SV40 min-luciferase construct
in pCI-neo and selecting stable colonies after G418 exposure.
Colonies exhibiting robust HRE-mediated luciferase induction
after hypoxic exposure were transfected with pEFIRESp encoding
renilla luciferase, selected using puromycin and monitored for
HRE-firefly luciferase and constitutive renilla luciferase expression
using the dual-luciferase reporter assay following the manufac-
turer’s guidelines (Promega, Southampton, UK).
Immunohistochemistry
Spheroids were fixed in 4% buffered formalin overnight at 41C and
paraffin embedded. Sections were cut (B4mm) and immunostain-
ing was performed after dewaxing in xylene and rehydration in
graded alcohols. Antigen retrieval was carried out by microwaving
(800W, 20min) and cooling (15min) in 10mM citrate buffer, pH
6.0. Sections were blocked (0.1 M Tris-HCl, 0.15 M NaCl, pH 7.5, 4%
normal goat serum (Dako, Glostrup, Denmark) for 2h and
incubated overnight at 41C with primary antibody or antibodies:
cleaved caspase-3, (1 in 100, CC3, Cell Signalling Technologies,
Hitchin, UK), Ki67 (1 in 100, Clone MIB-1, Dako, Ely, UK) or
GLUT-1 (1 in 100, Autogen Bioclear, Calne, UK). Negative controls
consisted of substituting the primary antibody with mouse IgG1
or rabbit IgG at the same dilution. Sections were incubated
with Alexa-conjugated donkey anti-mouse or donkey anti-rabbit
immunoglobulin for 2h (1 in 1000, Invitrogen), and then mounted
using Prolong Gold Antifade containing DAPI (Invitrogen). Slides
were viewed and images captured using an Olympus BX51
microscope. The intensity for each fluorescence channel was
plotted from the necrotic core’s edge to the outer rim using ‘plot
profile’ in ImageJ (Wayne Rasband, NIH, Bethesda, MD, USA).
Fluorescence intensity for CC3 and Ki67 staining was normalised
to DAPI (accounting for changes in cellularity) and distances were
converted into % penetrance.
Cell viability and clonogenicity
Cells were plated either in T25 flasks (5ml media, Corning, Amsterdam,
The Netherlands) for clonogenic assays or in 96-well plates (100ml
media per well, Falcon, via Scientific Laboratory Supplies,
Nottingham, UK), and were allowed to adhere for 16h before
incubation in standard atmospheric (5% CO2/air) or hypoxic
conditions for 8h before drug treatment. Cells were maintained in
hypoxic or standard atmospheric conditions and drugs adminis-
tered for 16h. Media were replaced and cells incubated under
normoxia for 6 days before SRB assay as previously described
(Vichai and Kirtikara, 2006), and the concentration that reduced
growth by 50% (IC50) was determined. Clonogenicity after a 16h
drug exposure was determined as previously described (Williams
et al, 2002). IC50 was the concentration resulting in a surviving
fraction of 0.5 compared with untreated cells.
Fluorescence-activated cell sorting
Spheroids were washed with fresh media and incubated (20min,
371C) with 10mM Hoechst 33342 (Invitrogen). After a PBS wash,
spheroids were dissociated with trypsin (Invitrogen, 0.5%, 10min),
centrifuged and resuspended in fresh media at 10
7cellsml
 1 before
sorting into four fractions on the basis of Hoechst 33342
fluorescence using a BD FACSAria (Becton Dickinson, Oxford,
UK). Debris was gated out and the brightest (B) and dimmest (D)
15% cells were sorted, with the remaining cells being equally
distributed into medium-dim (MD) and medium-bright (MB)
fractions. Sorted fractions were plated for clonogenic survival,
assayed for luciferase activity (reporter cell lines) or used for
determination of platinum (Pt) adduct levels after drug treatment.
The oxaliplatin concentration required to kill 90% cells in each
sorted sub-population was compared with that required to kill 90%
of the bright (B), outermost fraction. A relative resistance value
was calculated as the dose modification factor (DMF) for 90% cell
kill (ratio of dose required to kill 90% cells in the inner-fractions
compared with that in the B fraction).
Oxaliplatin adduct quantification
Total intracellular Pt levels were determined from monolayers or
from sorted spheroid sub-populations. Cells were resuspended in
ice-cold 10mM Tris-HCl, 1% Triton-X100 pH 7.5 containing protease
inhibitor cocktail and were sonicated to lyse cells and fragment DNA.
Proteins were hydrolysed with NaOH and the remaining DNA was
hydrolysed with nitric acid. Samples were stored at  801C. Nitric
acid (67–70%) was Optima grade for trace metal analysis (Fisher
Scientific). Cellular Pt content was determined using a magnetic
sector ICP-MS (Thermo Element 2) with a low uptake nebuliser. To
correct for and measure any signal suppression due to sample matrix
effects, all standards, blanks and samples contained thallium (Tl) as
internal standard; hafnium (Hf) was also monitored as described
previously (John et al, 2003). Platinium concentrations were derived
by reference to a standard solution calibration curve using the mean
concentration from the three Pt isotopes.
Statistical analysis
Two-tailed t-tests were used to evaluate significant differences.
P-values of o0.05 were considered as statistically significant.
RESULTS
Previous studies established that CRC cells resist a number of
chemotherapeutics under hypoxic conditions (Erler et al, 2004). In
this study, hypoxic HCT116 cells were found to be resistant to
oxaliplatin using short-term SRB (IC50 normoxia¼5.2mM vs IC50
hypoxia¼10.1mM, P¼0.015) and clonogenic survival end points
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s(IC50 normoxia 2.4mM vs IC50 hypoxia 5.9mM; Figure 1). The IC50
for oxaliplatin under hypoxia was 1.9- and 2.4-fold higher than
that in normoxia for SRB and clonogenic assays, respectively.
Hypoxic cells within multicellular CRC spheroids were
oxaliplatin resistant
To investigate cellular response to chemotherapy in a more
physiologically relevant model, HCT116 cells were grown as three-
dimensional spheroids. Figures 2A and B show that untreated
spheroids have a high proportion (490%) of proliferating cells
(Ki67 positive), except in peri-necrotic regions (o15% positive),
whereas apoptosis (CC3 positivity) was observed in o10% cells
(n¼10). Treatment with 5–10mM oxaliplatin decreased Ki67
staining. At 25mM, oxaliplatin increased Ki67 staining, a para-
doxical result most likely explained by nuclear fragmentation. An
oxaliplatin concentration-dependent increase in CC3 staining was
observed to be restricted to the outer rim, suggesting that response
of inner cells may be dependent on their oxygenation and/or
nutrient status and/or drug penetration through the cell mass.
Similar results were observed using dual staining; Ki67 stained in
outer and peri-necrotic regions, whereas CC3 was only evident in
outer regions (Figure 2B). Staining specificity was ascertained
using MCF-7 cell pellets (caspase-3 null) and staurosporine-treated
HUVEC cells as negative and positive controls, respectively.
To investigate the relationship between proliferation, cell death
and cellular location, staining was repeated on oxaliplatin-treated
spheroids using immunofluorescent detection for direct compar-
ison of respective biomarkers (Figure 2B and C). Ki67 staining
decreased significantly towards the necrotic core (the outermost
10% of the spheroid compared with the innermost 10%,
Po0.0001), and this pattern did not change with oxaliplatin
treatment. Staining for CC3 was significantly higher in the outer
50% cells within treated spheroids (Po0.0001) compared with the
inner 50%. Cell sub-populations were isolated to assess any
relationship between histology and cell survival. After exposure to
oxaliplatin for 1h, spheroids were treated with Hoechst 33342,
disaggregated and sorted into four sub-populations: bright (B),
medium-bright (MB), medium-dim (MD) and dim (D). Those cells
with high fluorescence (B) come from the outer, well-oxygenated
regions, whereas cells showing low fluorescence (D) arise from
inner, hypoxic regions (Olive et al, 1985). Consistent with the
immunohistochemistry analysis, Figure 3A shows that D and MD
sub-populations had significantly increased IC50 values compared
with B sub-population cells (values were calculated from raw data
for each experiment and averaged to give IC50 (D), 19.67mM, (MD)
17.45mM compared with (B) 13.0mM, P¼o0.0001). Increasing
oxaliplatin exposure from 1 to 24h revealed a similar trend (data
not shown). These data also demonstrate that culture of cells in a
three-dimensional system alters their response to oxaliplatin, as
revealed by comparing the outer cell response to that of control
monolayers; this reveals that cells grown in three dimensions are
inherently more resistant (B sub-population IC50,1 3 mM, control
monolayer IC50, 2.4mM).
Reduced drug uptake/retention in hypoxic cells within
spheroids did not account fully for reduced cytotoxicity
To investigate whether the change in cell survival throughout
spheroids was due to differential oxaliplatin bioavailability, Pt-adduct
formation was analysed in sorted sub-populations using Inductively
Coupled Plasma Mass Spectroscopy (ICP-MS; Table 1). After
exposure to oxaliplatin (25mM, 2h), cells were sorted into D, MD,
MB and B sub-populations and adducts were expressed as % Pt-
adducts in the B sub-population. Adduct formation was reduced by
1.3-fold and 1.5-fold in MD and D cells, respectively, compared with
that observed in the B sub-population. However, survival was
increased after exposure to oxaliplatin from SF 0.02 for the B sub-
population to 0.157 for MD and 0.22 in D sub-populations (increasing
7.8-fold from B to MD and 11-fold from B to D, Figure 3A).
To investigate whether the observed changes in Pt-adduct
formation merely reflected oxaliplatin penetrance through spher-
oids, HCT116 monolayers were treated with oxaliplatin, and
adduct formation was analysed after 21 or 1% oxygen exposure.
Interestingly, adduct formation was also reduced significantly in
hypoxia (P¼0.013 at 10mM, P¼0.026 at 25mM) in which there was
no biophysical hindrance to drug exposure (Figure 3B). Taken
together with relative survival data (Figure 3A), this suggests that
mechanisms other than drug penetrance contribute to oxaliplatin
resistance in hypoxic cells within spheroids.
Monolayer cultures of HCT116 that lack HIF function did
not show hypoxic resistance to oxaliplatin
Our previous studies using monolayers implicated HIF-1 in hypoxic
resistance to chemotherapeutics (Erler et al, 2004; Brown et al, 2006).
To facilitate the extrapolation of these observations to spheroids,
stable HCT116 cell lines were generated to express a DN variant of
HIF-1a (Brown et al, 2006). Control cells expressed an EV.
Expression of DN HIF-1a ablated HIF-1-mediated reporter gene
expression after exposure to cobalt chloride (Figure 4A), as well as
the expression of the HIF-1 target GLUT-1 (Figure 4B). Expression of
native HIF-1a protein was unaffected by the DN variant, but hypoxia-
induced expression of GLUT-1 was absent from DN cells grown as
monolayers or as spheroids (Figure 4B and C). In EV spheroids,
GLUT-1 localised to the hypoxic, peri-necrotic areas corresponding
to regions labelled by the hypoxia biomarker pimonidazole
(Figure 4C, data not shown). Glucose transporter-1 staining was
not seen in hypoxic regions of DN spheroids (Figure 4C). Exposure
of monolayer EV cells to oxaliplatin revealed hypoxic resistance
by SRB assay (Figure 5A), which matched that of parental cells
(IC50 hypoxia/IC50 a i r1 . 4 - f o l d ,n o ts h o w n ) .H o w e v e r ,n oh y p o x i c
resistance to oxaliplatin was observed in DN cells, demonstrating an
HIF-1-dependent resistance mechanism (Figure 5A). Similar results
were observed on inhibition of HIF-1 function through DN
expression in HT1080 human fibrosarcoma cells exposed to 5mM
oxaliplatin for 24h (Supplementary Figure 1).
The differences in response between HCT116 cells with and
without functional HIF was independent of oxaliplatin
uptake
To ensure that changes in oxaliplatin sensitivity were not due
to differential drug uptake between EV and DN cells, Pt-adduct
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Figure 1 Hypoxia-induced oxaliplatin resistance. HCT116 cells were
exposed to normoxia or hypoxia for 8h and were treated with oxaliplatin
(0–25mM) for 16h under continued normoxia or hypoxia. Clonogenic
survival was assessed 6–10 days later. The surviving fraction was
determined from the mean of two experiments, each containing a range
of cell densities in duplicate.
Oxaliplatin response in colorectal cancer spheroids
DL Roberts et al
1292
British Journal of Cancer (2009) 101(8), 1290–1297 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sformation was assessed in monolayers exposed to a range of
oxaliplatin concentrations under normoxia or hypoxia (Figure 5B).
A concentration-dependent increase in protein-Pt-adduct forma-
tion was revealed in EV and DN cells under both conditions.
The adduct formation was reduced in hypoxia vs normoxia
for both cell lines, consistent with data from untransfected
cells (Figure 3), suggesting that modification of oxaliplatin
uptake/retention under hypoxic conditions is independent of
HIF function.
Lack of HIF function ablated hypoxic resistance to
oxaliplatin in cells derived from spheroids
Oxaliplatin sensitivity was investigated in sorted sub-populations
of EV and DN spheroids. Initial studies were undertaken to
validate whether sub-populations showed differences in HIF
activity using spheroids of HCT116 HIF-1 reporter cells. These
cells express firefly luciferase under the transcriptional regulation
of HIF-1 (through inclusion of a trimer sequence of the lactase
No primary Ab Ki67 Cleaved caspase-3
MCF-7
HUVEC
100 m
50 m
100 m
100 m
100 m
0 M
5 M
10 M
25 M
Figure 2 The effect of oxaliplatin on proliferation and apoptosis in spheroids. Spheroids were treated with oxaliplatin (0–25mM) for 24h before fixation,
processing and immunohistochemical assessment of Ki67 or cleaved caspase-3 (CC3) (A). Specificity of CC3 staining was confirmed using positive and
negative cell pellets. The staining shown is representative of three separate experiments. Scale bars indicate either 100mm (controls and CC3) or 50mm
(Ki67). Studies were repeated using immunofluorescence (B), and localisation of biomarkers was confirmed by the assessment of fluorescent intensity across
spheroid sections (C). Sections were stained for Ki67 (green) and CC3 (red) with DAPI (blue) counterstaining to identify nuclei (B). Scale bars¼50mm. The
fluorescent profile in each channel was plotted from the necrotic core to the outer rim and compared between treated and control sections to correlate
staining with positional information (C). Plots are the mean intensity of 14 spheroids for each condition.
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sdehydrogenase promoter) and a renilla luciferase construct under
the regulation of the strong constitutive promoter elongation
factor-1a. The expression level of firefly luciferase relative to
renilla luciferase in each sub-population was compared with that
obtained from whole-spheroid lysates (Figure 6A). The relative
level of HIF-1-driven firefly luciferase expression compared with
that of renilla luciferase was 56% lower in the outer spheroid
regions compared with the inner region (D), and increased in a
step-wise manner to the inner regions (Figure 6A), confirming that
spheroid sub-populations differed in their HIF-transactivation
levels.
Empty vector and DN spheroids were exposed to oxaliplatin
after sorting to exclude potential changes in penetrance that could
confound HIF-mediated effects. The response of the outer two
fractions (B and MB) was almost identical for both cell types
(Figure 6B and C), with greater sensitivity observed in outermost
cells. However, whereas the inner two sub-populations (D and
MD) of EV spheroids showed resistance to oxaliplatin treatment,
this was not apparent in DN cells isolated from the same sub-
populations. Relative resistance factors were calculated for the
sub-populations by determining the DMF required for 90% kill
compared with that of the B sub-population. The DMFs for MB,
MD and D populations were 1.4, 1.9 and 2.1, and 1.3, 1.4 and 1.4
for the EV- and DN-derived spheroid populations, respectively
(Figure 6B and C, data not shown). As during this experiment cells
were re-oxygenated during the period of drug exposure, we
investigated how re-oxygenation affected the hypoxia-induced
changes in the levels of GLUT-1 (upregulated by HIF-1) and Bax
(repressed by hypoxia independent of HIF-1) at the protein level
(Supplementary Figure 2). This revealed that changes in protein
levels were maintained for 8–12h on re-oxygenation, indicating
that our sorted fractions maintained a hypoxic ‘phenotype’ during
post-sort drug exposures.
DISCUSSION
This study investigated oxaliplatin sensitivity in HCT116 CRC cells
using both monolayers and spheroids to identify relative
contributions of physical vs biological mechanisms of hypoxic
resistance to chemotherapy. In monolayers, in which issues of
exposure and biodistribution are eliminated, oxaliplatin was less
effective in hypoxic compared with aerobic cells. Interestingly,
Pt-adduct formation was reduced markedly in hypoxic cells
exposed to oxaliplatin, which could contribute to the observed
differential toxicity. Treatment of cells with oxaliplatin at concen-
trations greater than clonogenic IC50 suggested that apoptosis
was dependent on the generation of reactive oxygen species
(Berndtsson et al, 2007), which would be compromised in hypoxia.
Consistent with data from monolayers, sensitivity to oxaliplatin
treatment was greater in cells of the outer, better-oxygenated
regions of HCT116 spheroids. Oxaliplatin provoked concentration-
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Figure 2 Continued.
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sdependent increases in apoptosis in outer regions, whereas it had
minimal impact on proliferation throughout the spheroid. When
spheroids were fractionated after oxaliplatin treatment, clonogenic
survival observed in outer region cells was eightfold higher than
that in innermost cells. The difference in Pt-adduct formation
between these two sub-populations was lower (1.5-fold reduction).
This suggests that compromised bioavailability was not the major
mechanism underpinning the poorer response of hypoxic cells
to oxaliplatin treatment. Furthermore, it suggests that in more
physiologically relevant culture models, cellular ‘handling’ of
oxaliplatin is markedly different to that observed in monolayers
and that in these models, adduct formation is not a reliable
biomarker for cytotoxicity per se.
In this study, a genetic approach was used to inhibit HIF-1
function in HCT116 cells by the introduction of a DN HIF-1a
subunit. Oxaliplatin was equitoxic to control monolayers of DN or
EV cells. However, whereas hypoxia induced resistance in EV cells,
in DN cells hypoxic sensitivity was equivalent to that in air.
Oxaliplatin adduct formation was unaltered by ablated HIF
function. In fractionated spheroids, the outermost cells exhibited
similar responses to oxaliplatin (SF 10mM oxaliplatin 0.061 EV vs
0.066 for DN), consistent with monolayers. However, cells from
the inner regions of DN spheroids were more sensitive than were
their EV counterparts. The level of sensitisation within spheroid
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Figure 3 Effect of oxaliplatin on cell survival in spheroids and
quantification of platinum adducts. Spheroids were treated with oxaliplatin
(0–25mM) for 1h and then fractionated. Clonogenicity was determined
and the surviving fraction plotted for each sub-population and oxaliplatin
concentration (A). Monolayer samples were assessed for total platinum
levels by ICP-MS (B). Platinum values are given as fmolesmg
 1 protein.
Data are the mean of three experiments (±s.e.).
Table 1 Distribution of platinum (Pt)-adduct formation in HCT116
spheroids
Bright Medium-bright Medium-dim Dim
Percentage (%) Pt 100 95.994 76.361 66.020
s.e. — 4.615 8.839 4.333
P-value vs bright — 0.4344 0.0555 0.0014
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Figure 4 Validation of the HCT116 DN model. HCT116 cells were stably transfected with an empty vector cassette (EV) or an hypoxia-inducible factor
(HIF)-a dominant-negative construct (DN). Altered HIF-1 function was validated using an HIF reporter assay analysed in the presence or absence of hypoxia
mimetic cobalt chloride (A) and by immunoblot analysis of the HIF-1 target glucose transporter-1 (GLUT-1) (B). At B500mm, HCT116 wild type, EV or
DN spheroids were treated with 100mM pimonidazole, fixed, sectioned and immunostained for GLUT-1 and pimonidazole adducts (C). Data are from a
representative experiment showing the mean ±s.d. of triplicate samples (A); immunoblots (B) and immunostaining (C) are representative of three separate
experiments. Scale bars indicate 100mm.
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ssub-populations correlated with HIF-1 activity determined using
fractionated sub-populations from HCT116 cells expressing an
HIF-1 responsive-luciferase reporter.
Taken together, these data suggest that HIF-1 has an important
role in mediating oxaliplatin sensitivity in HCT116 cells. Given our
previous findings, as well as those of others, hypoxic cell chemo-
resistance is predicted to be a strong contributor to the poor
response of CRC to standard therapies. A potential contribution
of HIF-1 to this phenotype is supported by clinical studies
demonstrating HIF-1a expression as a poor prognostic indicator in
CRC (Lu et al, 2006). The mechanisms by which HIF-1 contributes
to resistance are likely to be complex and varied depending on cell
genotype. Indeed, recent data observing sensitisation to cisplatin
using HIF-targeting RNAi suggest that reversal of hypoxic
resistance is p53 dependent (Hao et al, 2008). We previously
reported that HIF-1 can alter the balance of pro- and anti-
apoptotic proteins under hypoxic conditions (Erler et al, 2004).
Specifically, HIF-1 can downregulate pro-apoptotic Bid, the
reversal of which is associated with enhanced chemotherapy
response (Brown et al, 2006). The reciprocal relationship between
HIF-1a and Bid expression is maintained in clinical samples of
CRC, supporting its potential importance (Seenath et al, 2008).
With current interest in the development of HIF-targeting agents
as novel cancer therapies, these data would support their
exploitation in combination with standard chemotherapy to
enhance the treatment response in CRC.
ACKNOWLEDGEMENTS
This work was supported by a CR-UK project grant to IJS, CD and
KJW (C84/A4394) and by programme support from MRC (IJS and
KJW, G0500366) and CR-UK (CD, C147/A6058). We thank Gary
Ashton and Caron Abbey (Histology Service, Paterson Institute),
Mike Hughes and Jeff Barry (FACS Service, Paterson Institute) and
Steve Bagley (Advanced Imaging Facility, Paterson Institute).
Conflict of interest
The authors declare no conflict of interest.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
0
0.2
0.4
0.6
0.8
1
1.2
Dim Medium dim Medium bright Bright
R
e
l
a
t
i
v
e
 
f
i
r
e
f
l
y
 
l
u
c
i
f
e
r
a
s
e
a
c
t
i
v
i
t
y
Oxygen tension
0.01
0.1
1
02468 1 0
Bright
Medium bright
Medium dim
Dim
HCT116 EV
M Oxaliplatin
02468 1 0
M Oxaliplatin
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
0.01
0.1
1
Bright
Medium bright
Medium dim
Dim
HCT116 DN
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
Figure 6 Hypoxia-inducible factor (HIF) activity correlated with
oxaliplatin resistance in spheroid cultures. A HCT116 reporter cell line
stably expressing a constitutive renilla luciferase and hypoxia-induced
(LDH-HRE) firefly luciferase was used to validate the fractionation
methodology. Hypoxia-inducible factor-1 activity was measured in sorted
spheroid sub-populations by determining the relative expression of firefly
to renilla luciferase (A). HCT116 EV (B) and DN (C) spheroids were
fractionated on the basis of Hoechst 33342 fluorescence and the resulting
sub-populations were exposed to various concentrations of oxaliplatin. Cell
survival was assessed by clonogenic assay. Data are the mean of three
experiments ±s.e.
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Figure 5 Hypoxic resistance was hypoxia-inducible factor (HIF)
dependent and unrelated to platinated-DNA adduct formation. Empty
vector (EV) and dominant-negative (DN) cells were exposed to oxaliplatin
under standard atmospheric or hypoxic conditions, and IC50 values were
calculated from SRB assays (A). Total cellular platinum concentrations were
determined in control or hypoxic EV and DN cells after oxaliplatin
exposure (B). Data are the mean of three experiments ±s.e.
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